Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;43(2):280-284.
doi: 10.1002/cac2.12368. Epub 2022 Nov 4.

Weakened humoral immune responses of inactivated SARS-CoV-2 vaccines in patients with solid tumors

Zhiwei Chen  1 , Peng Zhu  2 , Zuojin Liu  3 , Bin Zhu  4 , Guobing Yin  5 , Jia Ming  5 , Rui Song  1 , Qingbo Pan  1 , Tong Li  2 , Xingwei Jiang  6 , Bing Wang  4 , Shuaibin Liu  6 , Hongxing Cai  2 , Jingjie Wang  2 , Yuling Han  5 , Zijing Lin  5 , Yang Hong  6 , Min Chen  1 , Mingli Peng  1 , Lina Hu  6 , Dachuan Cai  1 , Hong Ren  1
Affiliations

Weakened humoral immune responses of inactivated SARS-CoV-2 vaccines in patients with solid tumors

Zhiwei Chen et al. Cancer Commun (Lond). 2023 Feb.
No abstract available

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Humoral immune responses following immunization with inactivated vaccines in patients with solid tumors. (A)The titers of antibodies in cancer patients and healthy controls. Left panel: anti‐RBD‐IgG titer; Right panel: NAbs titer. (B) The titers of antibodies in different treatment time groups of cancer patients. Left panel: anti‐RBD‐IgG titer; Right panel: NAbs titer. (C) The titers of antibodies in different treatment modalities groups of cancer patients. Left panel: anti‐RBD‐IgG titer; Right panel: NAbs titer. (D) The titers of antibodies over time in cancer patients and healthy controls. Left panel: anti‐RBD‐IgG titer; Right panel: NAbs titer. (E) The overall frequency (percentage of total B cells) of RBD‐specific MBCs in cancer patients and healthy controls. (F) The percentage of atyMBCs in cancer patients and healthy controls. (G) The change of RBD‐specific MBCs over time in cancer patients and healthy controls. (H) The change of atyMBCs over time in cancer patients and healthy controls. (I) The frequency of RBD‐specific MBCs in different treatment time groups of cancer patients. (J) The frequency of RBD‐specific MBCs in different treatment modalities groups of cancer patients. The trend lines of panel (D), (G) and (H) were produced using a single linear model fit, and the shaded area showed the 95% confidence interval for each fit. A two‐sided Spearman test was used to calculate the p‐values and rs correlation coefficients are color‐coded for each subgroup. The horizontal dotted line of panel (A), (B) and (C) represent the negative boundary value of antibody. The error bars represent median (IQR). Anti‐RBD‐IgG, spike receptor‐binding domain IgG antibody; atyMBCs, atypical MBCs; IQR, interquartile range; MBCs, memory B cells; NAbs, neutralizing antibodies.
See this image and copyright information in PMC

References

    1. Becerril‐Gaitan A, Vaca‐Cartagena BF, Ferrigno AS, Mesa‐Chavez F, Barrientos‐Gutiérrez T, Tagliamento M, et al. Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2) infection after Coronavirus Disease 2019 (COVID‐19) vaccination in patients with cancer: a systematic review and meta‐analysis. Eur J Cancer. 2022;160:243‐60. - PMC - PubMed
    1. Malik JA, Ahmed S, Mir A, Shinde M, Bender O, Alshammari F, et al. The SARS‐CoV‐2 mutations versus vaccine effectiveness: New opportunities to new challenges. J Infect Public Health. 2022;15(2):228‐40. - PMC - PubMed
    1. Goshen‐Lago T, Waldhorn I, Holland R, Szwarcwort‐Cohen M, Reiner‐Benaim A, Shachor‐Meyouhas Y, et al. Serologic Status and Toxic Effects of the SARS‐CoV‐2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer. JAMA Oncol. 2021;7(10):1507‐13. - PMC - PubMed
    1. Corti C, Antonarelli G, Scotté F, Spano JP, Barrière J, Michot JM, et al. Seroconversion rate after vaccination against COVID‐19 in patients with cancer‐a systematic review. Ann Oncol. 2022;33(2):158‐68. - PMC - PubMed
    1. Mair MJ, Berger JM, Berghoff AS, Starzer AM, Ortmayr G, Puhr HC, et al. Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS‐CoV‐2 Vaccinations. JAMA Oncol. 2022;8(1):106‐13. - PMC - PubMed

Publication types

Substances